Health
globalreutersDecember 2, 20241 Mins read
Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited Metabolic Disease
globalreutersDecember 2, 20241 Mins read 
The FDA cited deficiencies in its govorestat’s application in galactosemia, a rare metabolic disease, Applied Therapeutics said. The biotech is still on track to submit a separate application for the drug in sorbitol dehydrogenase (SORD) deficiency, another rare disease that has no FDA-approved therapies.
The post Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited Metabolic Disease appeared first on MedCity News.
Leave a comment